Gerresheimer AG: Broad approval at the Annual General Meeting

 - Gerresheimer AG
  • Dividend: EUR 1.25 per share after strong 2023 financial year
  • Gradual renewal of the Supervisory Board continues: three new shareholder representatives
  • High attendance and broad approval for all agenda items


Düsseldorf, 5 June 2024. The Annual General Meeting of Gerresheimer AG expressed its confidence in the Management Board and Supervisory Board with high approval rates for all items on the agenda. For the very successful 2023 financial year, the company will pay its shareholders a dividend of 1.25 euros. Three new Supervisory Board members were elected on behalf of the shareholders, thus continuing the gradual renewal of the Supervisory Board. In his speech, CEO Dietmar Siemssen emphasized the company's growth opportunities through its successful transformation into a system and solution provider. With specially tailored solutions for biopharmaceuticals, including solutions for GLP-1 drugs for the treatment of obesity, the perception of Gerresheimer in the market has changed for the better. As a strategic key partner for the global pharma and biotech industry, the "new" Gerresheimer is now benefiting significantly from market trends. The CEO also addressed the opportunities offered by the planned acquisition of Bormioli Pharma. 

"With the consistent implementation of our formula g growth strategy, we are growing sustainably and profitably and have created a strong foundation for long-term value creation. Today, we are a profitable growth company!" said Dietmar Siemssen, CEO of Gerresheimer AG, in his speech. "The planned acquisition of Bormioli Pharma will further strengthen our market position and accelerate our transformation into a systems and solutions provider. We are shifting up a gear on our highly dynamic growth and transformation course."

On May 23, 2024, Gerresheimer signed a purchase agreement with funds advised by Triton for the acquisition of Blitz LuxCo Sarl, the holding company of the Bormioli Pharma Group. The transaction is still subject to customary closing conditions and approvals.

EUR 1.25 dividend after successful 2023 financial year
The Annual General Meeting approved a dividend of EUR 1.25 per share for the 2023 financial year. This corresponds to a payout ratio of around 28% of adjusted net income. The ratio is thus once again at the upper end of the range of 20 to 30% defined by Gerresheimer. The dividend is due for payment on June 10, 2024.

In the 2023 financial year, Gerresheimer consistently continued its profitable growth course with revenue of EUR 1.99 billion and adjusted EBITDA of EUR 404.5 million.

Three new members of the Supervisory Board
The terms of office of Dr. Karin Louise Dorrepaal, Dr. Peter Noé and Udo J. Vetter ended at the end of the Annual General Meeting. They were no longer available for re-election. Dr. Sidonie Golombowski-Daffner, Dr. Dorothea Wenzel and Dr. Christoph Zindel were newly elected to the Supervisory Board as shareholder representatives. The concept of a gradual renewal of the shareholder side on the Supervisory Board presented at the Annual General Meeting in 2022, was thus further implemented.

Broad approval
With 79.6% of the share capital present, the Annual General Meeting approved all voting items with high quotas. The actions of the executive board and the supervisory board were ratified with a large majority and the compensation report was approved. KPMG AG Wirtschaftsprüfungsgesellschaft, Düsseldorf, was elected as the auditor for the 2024 financial year.

The detailed voting results of the Annual General Meeting and the CEO speech at the Annual General Meeting can be found here.

The annual report can be found here.


About Gerresheimer
Gerresheimer is the global partner for the pharmaceutical, biotech and cosmetics industries as an innovative systems and solutions provider. The company offers a comprehensive portfolio of containment solutions for medicines, drug delivery systems and medical devices, as well as solutions for the healthcare industry. The range of services includes digital solutions for therapy support, drug pumps, syringes, pens, auto-injectors and inhalers as well as injection vials, ampoules, tablet containers, infusion, dropper and syrup bottles. Gerresheimer ensures that medicines reach patients safely and can be administered reliably. With 35 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for the regional markets. With around 12,000 employees, the company generated sales of around 2 billion euros in 2023. Gerresheimer AG is listed on the MDAX of the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6).


Contact Gerresheimer AG

MediaInvestor Relations

Jutta Lorberg
Head of Corporate Communication
T +49 211 6181 264

Marion Stolzenwald
Senior Manager Corporate Communication
T +49 172 2424185

Guido Pickert
Vice President Investor Relations
T +49 152 900 14145

Thomas Rosenke
Senior Manager Investor Relations
T: +49 211 6181-187


Contact us!

Communication & Marketing
Phone: +49 211 61 81 251